Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
- PMID: 21629292
- DOI: 10.1038/nrd3455
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Abstract
Despite having an abundant number of vessels, tumours are usually hypoxic and nutrient-deprived because their vessels malfunction. Such abnormal milieu can fuel disease progression and resistance to treatment. Traditional anti-angiogenesis strategies attempt to reduce the tumour vascular supply, but their success is restricted by insufficient efficacy or development of resistance. Preclinical and initial clinical evidence reveal that normalization of the vascular abnormalities is emerging as a complementary therapeutic paradigm for cancer and other vascular disorders, which affect more than half a billion people worldwide. Here, we discuss the mechanisms, benefits, limitations and possible clinical translation of vessel normalization for cancer and other angiogenic disorders.
Similar articles
-
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22. Curr Opin Genet Dev. 2011. PMID: 21106363 Review.
-
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.Int J Mol Sci. 2021 Apr 5;22(7):3765. doi: 10.3390/ijms22073765. Int J Mol Sci. 2021. PMID: 33916438 Free PMC article. Review.
-
Angiogenesis in cancer. Basic mechanisms and therapeutic advances.Hamostaseologie. 2012;32(2):105-14. doi: 10.5482/ha-1163. Epub 2011 Aug 12. Hamostaseologie. 2012. PMID: 21837355 Review.
-
Anti-angiogenic therapy: concept to clinic.Microcirculation. 2012 Feb;19(2):115-25. doi: 10.1111/j.1549-8719.2011.00147.x. Microcirculation. 2012. PMID: 22078005 Review.
-
Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.Eur J Cell Biol. 2006 Feb;85(2):61-8. doi: 10.1016/j.ejcb.2005.10.003. Epub 2005 Nov 11. Eur J Cell Biol. 2006. PMID: 16439306 Review.
Cited by
-
Group XIV C-type lectins: emerging targets in tumor angiogenesis.Angiogenesis. 2024 Mar 12. doi: 10.1007/s10456-024-09907-x. Online ahead of print. Angiogenesis. 2024. PMID: 38468017 Review.
-
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages.Biomark Res. 2024 Feb 28;12(1):29. doi: 10.1186/s40364-024-00573-1. Biomark Res. 2024. PMID: 38419056 Free PMC article.
-
Polypyrimidine tract-binding protein 3/insulin-like growth factor 2 mRNA-binding proteins 3/high-mobility group A1 axis promotes renal cancer growth and metastasis.iScience. 2024 Feb 9;27(3):109158. doi: 10.1016/j.isci.2024.109158. eCollection 2024 Mar 15. iScience. 2024. PMID: 38405614 Free PMC article.
-
Identification of a lipid homeostasis-related gene signature for predicting prognosis, immunity, and chemotherapeutic effect in patients with gastric cancer.Sci Rep. 2024 Feb 5;14(1):2895. doi: 10.1038/s41598-024-52647-7. Sci Rep. 2024. PMID: 38316848 Free PMC article.
-
LUBAC promotes angiogenesis and lung tumorigenesis by ubiquitinating and antagonizing autophagic degradation of HIF1α.Oncogenesis. 2024 Jan 25;13(1):6. doi: 10.1038/s41389-024-00508-3. Oncogenesis. 2024. PMID: 38272870 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
